Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02626481Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Dec 2015
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by CHU de Lille. Started Dec 2015; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02626481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626481.